Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of tocilizumab (LZM008) for rheumatoid arthritis
ChiCTR2500096500Phase 4Not yet recruiting
- Sponsor
- Affiliated Hospital of North Sichuan Medical College
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tocilizumab in rheumatoid arthritis (RA), sponsored by Affiliated Hospital of North Sichuan Medical College. Primary endpoint: Proportion of subjects achieving ACR20 at week 24. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ChiCTR2500096500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096500.